Effectiveness of Atorvastatin in Preventing Cerebrovascular Events After Flow Diverter Implantation

Conditions: Efficacy Endpoint: no New Cerebrovascular Adverse Events Within 1 Year; Safety Endpoint: no New Moderate or Serious Adverse Events Within 1 Year; All-cause Mortality Events (Within 1 Year); Incident Ischemic Stroke Events (Within 1 Year); New Hemorrhagic Stroke Events (Within 1 Year); New Stent Thrombosis Events (Within 1 Year); New Symptomatic Stenosis Events (Within 1 Year); Occurrence of In-stent Stenosis 12th ±1 Month Annual Angiographic Follow-up; Degree of In-stent Stenosis (as Measured by WASID Method) at the 12th ±1 Month Annual Angiographic Follow-up; Target Aneurysm Embolization Rate at 12±1 Month Annual Angiographic Follow-up (Raymond and OKM Classification) Interventions: Drug: Atorvastatin 20mg Sponsors: Zhujiang Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials